Identification and Construction of Prognostic Clusters and Risk-prognosis Model Based on Aging-immune Related Genes in Bladder Cancer

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 4

PMID 39630308

Authors

Nihao Cao

Fei Cheng

Jincai Zhou

Ning Liu

Affiliations

Soon will be listed here.

Abstract

Background: Faced with the current global ageing situation, advanced age has become a risk factor for bladder carcinogenesis progression and immunotherapy. Exploring the common mechanisms of aging and immune in bladder cancer and finding new prognostic markers and immunotherapeutic targets has become an urgent issue.

Method: Aging-immune related genes (AIGs) were collected from the public databases MSIGDB, HAGR and ImmPort, and hub AIGs were finally identified in the TCGA-BLCA disease cohort by expression, prognosis, and clinicopathological correlation analysis, and the correlation of hub AIGs with immune microenvironment, immunotherapeutic response, ferroptosis and m6A methylation was verified. Subsequently, prognostic clusters and risk-prognosis models for AIGs was constructed by cluster analysis and multifactorial Cox regression analysis, and the gene mutation and immune infiltration characteristics of the different clusters were explored. Finally, the expression level of related genes was verified by immunohistochemical experiments using patient samples from our medical center.

Result: 145 potential prognostic AIGs were collected in bladder cancer and finally clarified NFKB1 and IL7 with significant expression differences, prognostic value and age correlation. By single gene analysis, hub AIGs were explored to be significantly correlated with immunotherapeutic response, immune microenvironment, ferroptosis and m6A methylation. Subsequently, the risk-prognosis model was constructed with Riskscore = (0.0581)*NFKB1 + (- 0.2285)*IL7. And prognostic clusters based on hub AIGs was performed by cluster analysis, which clarified that the high-risk group was the pro-cancer group, which had a lower mutation rate of hub genes and higher of neutrophil infiltration. Finally, immunohistochemistry of patients confirmed that IL7 and NFKB1 were underexpressed in bladder cancer, and the proliferation and migration ability of tumor cells were significantly decreased after overexpression of these genes.

Conclusion: This study is the first to identify NFKB1 and IL7 as hub AIGs in bladder cancer, which provide new prognostic markers and immunotherapeutic targets.

References

Passtoors W, van den Akker E, Deelen J, Maier A, van der Breggen R, Jansen R . IL7R gene expression network associates with human healthy ageing. Immun Ageing. 2015; 12:21. PMC: 4642670. DOI: 10.1186/s12979-015-0048-6. View

Ritch C, Velasquez M, Kwon D, Becerra M, Soodana-Prakash N, Atluri V . Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort. J Urol. 2019; 203(3):505-511. DOI: 10.1097/JU.0000000000000593. View

Shariat S, Sfakianos J, Droller M, Karakiewicz P, Meryn S, Bochner B . The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2009; 105(3):300-8. PMC: 4315315. DOI: 10.1111/j.1464-410X.2009.09076.x. View

Feehan J, Tripodi N, Apostolopoulos V . The twilight of the immune system: The impact of immunosenescence in aging. Maturitas. 2021; 147:7-13. DOI: 10.1016/j.maturitas.2021.02.006. View

Patel V, Oh W, Galsky M . Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020; 70(5):404-423. DOI: 10.3322/caac.21631. View

Riemann K, Becker L, Struwe H, Rubben H, Eisenhardt A, Siffert W . Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther. 2007; 45(8):423-30. DOI: 10.5414/cpp45423. View

Freedman N, Silverman D, Hollenbeck A, Schatzkin A, Abnet C . Association between smoking and risk of bladder cancer among men and women. JAMA. 2011; 306(7):737-45. PMC: 3441175. DOI: 10.1001/jama.2011.1142. View

Fane M, Weeraratna A . How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2019; 20(2):89-106. PMC: 7377404. DOI: 10.1038/s41568-019-0222-9. View

Nguyen V, Mendelsohn A, Larrick J . Interleukin-7 and Immunosenescence. J Immunol Res. 2017; 2017:4807853. PMC: 5397725. DOI: 10.1155/2017/4807853. View

10.

Xia Y, Chen S, Cui J, Wang Y, Liu X, Shen Y . Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p. Biochem Pharmacol. 2021; 188:114575. DOI: 10.1016/j.bcp.2021.114575. View

11.

Santoro A, Bientinesi E, Monti D . Immunosenescence and inflammaging in the aging process: age-related diseases or longevity?. Ageing Res Rev. 2021; 71:101422. DOI: 10.1016/j.arr.2021.101422. View

12.

Zhou R, Liang J, Tian H, Chen Q, Yang C, Liu C . An Immunosenescence-Related Gene Signature to Evaluate the Prognosis, Immunotherapeutic Response, and Cisplatin Sensitivity of Bladder Cancer. Dis Markers. 2022; 2022:2143892. PMC: 8915927. DOI: 10.1155/2022/2143892. View

13.

Carlo M, Ravichandran V, Srinavasan P, Bandlamudi C, Kemel Y, Ceyhan-Birsoy O . Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. J Clin Oncol. 2019; 38(5):406-414. PMC: 7351337. DOI: 10.1200/JCO.19.01395. View

14.

Wallis C, Mahar A, Choo R, Herschorn S, Kodama R, Shah P . Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016; 352:i851. PMC: 4775870. DOI: 10.1136/bmj.i851. View

15.

Artis D, Shapira S, Mason N, Speirs K, Goldschmidt M, Caamano J . Differential requirement for NF-kappa B family members in control of helminth infection and intestinal inflammation. J Immunol. 2002; 169(8):4481-7. DOI: 10.4049/jimmunol.169.8.4481. View

16.

. . Aktuelle Urol. 2021; 52(1):25. DOI: 10.1055/a-1307-2419. View

17.

Joudi F, Smith B, ODonnell M, Konety B . The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006; 175(5):1634-9. DOI: 10.1016/S0022-5347(05)00973-0. View

18.

Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn B, Comperat E . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64(4):639-53. DOI: 10.1016/j.eururo.2013.06.003. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Derhovanessian E, Maier A, Beck R, Jahn G, Hahnel K, Slagboom P . Hallmark features of immunosenescence are absent in familial longevity. J Immunol. 2010; 185(8):4618-24. DOI: 10.4049/jimmunol.1001629. View